Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (299)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (13)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (299)
Apply filters
Showing 291 to 299 of 299
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Vibegron for treating symptoms of overactive bladder ID6300
Technology appraisal guidance
TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
Technology appraisal guidance
TBC
Voxelotor for treating sickle cell disease [ID1403]
Technology appraisal guidance
12 June 2024
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
Technology appraisal guidance
22 November 2017
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Technology appraisal guidance
TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
Technology appraisal guidance
17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Technology appraisal guidance
TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
Technology appraisal guidance
7 August 2024
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]
Technology appraisal guidance
23 October 2024
Previous page
1
…
28
29
Current page
30
Page
30
of
30
Results per page
10
25
50
All
Back to top